Richter Announces the Acquisition of PregLem

BUDAPEST, Hungary, October 7, 2010 - Richter announces the Acquisition of PregLem for an initial cash
consideration of CHF150 million (EUR114 million) and further milestone
payments of up to CHF295 million (EUR223 million). The Acquisition values
PregLem at up to CHF445 million (EUR337 million)

    - PregLem is a Swiss based, specialty biopharmaceutical company focused
      on the development and commercialisation of women's reproductive
      medicine

    - The Acquisition of PregLem:

    - Increases Richter's exposure to specialty pharma

    - Develops Richter Groups's presence in main European markets

    - Complements Richter's existing Women's Health franchise

    - Richter will invest at least CHF100 million in PregLem in
      2011-2013 to assist the commercial development of PregLem's product
      portfolio

Summary

Gedeon Richter Plc ("Richter") today announces the Acquisition of PregLem
Holding SA ("PregLem"), a privately held Swiss biopharmaceutical company
focused on the treatment of gynaecological conditions and infertility. The
Acquisition has completed and Richter now owns 100% of PregLem's equity.

PregLem's owners included Founders, Sofinnova Partners (Seed and Lead
investor), MVM International Life Sciences Partners, NeoMed Innovation,
Sofinnova Ventures, Sutrepa and managers and employees of PregLem.

The existing PregLem executive team will continue to manage PregLem which
will become a research and development centre of an enlarged and growing
Women's Health business for the Richter Group, with a core focus on the
development of early stage compounds. PregLem's senior management team have
extensive experience in women's reproductive medicine from leading
international pharmaceutical companies such as Serono (now Merck Serono),
Ipsen and Warner Lambert (now Pfizer).

PregLem's lead product, PGL4001 Esmya(TM), completed Phase III
clinical trials in June 2010 for the treatment of uterine myoma. PregLem
currently has five products in clinical and pre-clinical development. PregLem
will provide a further high added value pipeline to Richter's existing female
healthcare product portfolio, which itself has been based on well established
steroid chemistry knowledge.

The transaction values PregLem at up to CHF445 million provided certain
milestones are achieved, with the consideration to be settled in cash.
PregLem shareholders will receive CHF150 million in cash upfront and further
milestone payments of up to CHF295 million will be paid assuming achievement
of all milestone targets. Over the next three years, Richter is committed to
investing CHF100 million in PregLem to commercialise PregLem's products,
develop salesforce capability in the main European markets and progress the
clinical development of PregLem's early stage compounds.

Rationale for the Acquisition

PregLem represents a unique opportunity for Richter to
strengthen its core Women's Health business as it broadens Richter's
specialty pharma nature whilst at the same time complementing Richter's
existing Women's Health expertise and product range. This Acquisition will
develop Richter's presence in main European markets and in addition,
Richter's salesforce will sell PregLem's products in CEE and CIS countries.

Erik Bogsch, Managing Director of Richter, said:

"PregLem represents an outstanding strategic opportunity for the Richter
Group in a core therapeutic area. I look forward to working with the existing
management team to develop the PregLem products in the European markets."

Ernest Loumaye, CEO and Founder of PregLem, said:

"PregLem, in three years, has developed an innovative pipeline
of drugs for the treatment of benign gynaecological conditions.

This deal provides the opportunity to advance our portfolio of
products, to register ESMYATM (PGL4001) in Europe and to build a commercial
organisation in selected European countries. Richter's existing portfolio and
approach to specialty pharma is highly complementary and we look forward to
working together to bring products to market which will have a significant
impact on women's lives."

Principal terms of the Acquisition

Financial terms

(a) The initial purchase price for the shares in PregLem amounts to
CHF150 million

(b) In addition, upon the achievement of milestones, Richter will pay
PregLem's shareholders additional cash amounts, up to a maximum of CHF295
million

Capital injection

Richter committed to make equity capital contributions to PregLem in the
amount of CHF100 million, over the next three years, towards the funding of
assets, activities, employees and resources needed by PregLem to achieve the
milestones, clinical development of PregLem's early stage compounds and to
establish a marketing organisation in the UK, Germany, France, Italy and
Spain.

Information on PregLem

PregLem is a Swiss based, specialty biopharmaceutical company engaged in
the development and commercialisation of a new class of drugs for the
treatment of benign gynaecological conditions. PregLem focuses on women's
reproductive medicine with significant unmet medical needs, such as uterine
fibroids (myoma), endometriosis, infertility and post surgical abdominal
adhesions.

PregLem currently has five projects in clinical and
pre-clinical development. Its most advanced product, PGL4001 Esmya(TM),
completed Phase III clinical trials in June 2010 for the treatment of uterine
myoma, a common benign tumor in women of reproductive age. A European MAA
filing for Esmya(TM) is anticipated in Q4 2010.

PregLem was founded in Geneva in 2006 by two experienced
pharmaceutical industry executives: Dr Ernest Loumaye, a specialist in female
reproductive medicine, and Eric Rolin, a finance and business development
executive. PregLem was initially established to develop and commercialise
clinical and pre-clinical assets that were spun off from Ipsen Pharma
(PGL1001 and PGL2001). Subsequently, PregLem also in-licensed (PGL4001) from
HRA Pharma and PGL5001 from Merck-Serono.

Notes to media

A press conference will be hosted today at 11:30am (CET).

Evercore Partners is acting as exclusive financial adviser to Richter and
Bär & Karrer AG is acting as Richter's legal adviser. Credit Suisse is acting
as financial adviser to PregLem and Homburger AG is acting as sellers' legal
adviser.

Notes to Editors

About Richter Plc

Richter is a leading multinational pharmaceutical company headquartered
in Budapest, Hungary. With consolidated sales of approximately EUR1 billion
(US$1.3 billion) in 2009 and a market capitalization of EUR3.2 billion
(US$4.3 billion), Richter is one of the largest pharmaceutical companies in
Central Eastern Europe. Richter's core markets are in Central Eastern Europe
and the CIS and it has a growing presence in the US through its strategic
partners and in key EU countries through its commercial subsidiaries. The
product portfolio of the company covers most therapeutic areas, including
cardiovascular, central nervous system and gynaecology. Richter has the
largest R&D unit in Central Eastern Europe and its original research activity
focuses exclusively on CNS disorders with main clinical targets being
schizophrenia, anxiety, chronic pain and depression. With its widely
acknowledged steroid chemistry expertise, Richter is a significant player in
the female healthcare field worldwide.

    Enquiries:

    Richter
    Zsuzsa Beke, Public Relations
    +36-1-431-4888

    For Swiss press:
    PregLem
    Ernest Loumaye, CEO
    +41-22-884-0340

Enquiries: Richter, Zsuzsa Beke, Public Relations, +36-1-431-4888. For Swiss press: PregLem, Ernest Loumaye, CEO, +41-22-884-0340